Logo

Alnylam Signs CRADA With US Army to Develop RNAi-Based Antivirals

Apr 13, 2006

NEW YORK, April 13 (GenomeWeb News) - Alnylam Pharmaceuticals and the United States Army Medical Research Institute of Infectious Diseases plan to co-develop RNAi therapeutics targeting viruses, Alnylam said yesterday.

 

Under the Cooperative Research and Development Agreement, Alnylam will use its RNAi therapeutic platform to discover and develop agents against viruses posing "a serious biological threat to the military and public health," including hemorrhagic fever viruses, according to a company statement.

 

According to Alnylam, USAMRIID is "an organization which is uniquely positioned to collaborate in translational research for Biosafety Level 4 threats."

 

Last year, Alnylam signed a CRADA with the Department of Defense's DARPA unit to develop RNAi-based influenza therapeutics.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.